Evidence of Endothelial Dysfunction in Angiographically Normal Coronary Arteries of Patients With Coronary Artery Disease

Steven W. Werns, MD, Joseph A. Walton, MD, Henry H. Hsia, MD,
Elizabeth G. Nabel, MD, Mark L. Sanz, MD, and Bertram Pitt, MD

Acetylcholine causes endothelium-dependent dilation of normal arteries in most animal species. The effect of acetylcholine on normal human coronary arteries is controversial. Pathologic studies and epicardial echocardiography have shown that diffuse atherosclerosis is often present despite angiographic evidence of discrete coronary artery disease (CAD). Therefore, we postulated that acetylcholine would cause vasoconstriction of coronary arteries that are angiographically normal in patients with CAD. Coronary artery diameter, measured by automated quantification of digitized cineangiograms, was determined before and after the intracoronary infusion of 0.2 mM acetylcholine at 0.8–1.6 ml/min. The diameter of stenotic or irregular segments of six atherosclerotic coronary arteries decreased from 1.80±0.42 mm before acetylcholine to 1.26±0.46 mm after acetylcholine (p=0.0025). Acetylcholine had a significantly different effect on the diameter of two groups of coronary arteries that are angiographically normal. Acetylcholine caused a 0.16±0.09-mm increase in the diameter of 14 normal coronary arteries in patients without CAD, whereas it caused a 0.26±0.12-mm decrease in the diameter of 14 normal coronary arteries in patients with CAD (p<0.01). Thus, the normal response to intracoronary acetylcholine is vasodilation, suggesting that endothelium-derived relaxing factor is released from normal human coronary endothelium. The vasoconstrictive effect of acetylcholine in the angiographically normal coronary arteries of patients with CAD suggests the presence of a diffuse abnormality of endothelial function. (Circulation 1989;79:287–291)

There is growing evidence that acetylcholine and a number of other substances induce vasodilation by stimulating the release of an endothelium-derived relaxing factor (EDRF) from endothelial cells, whereas nitroglycerin and other endothelium-independent vasodilators induce vasodilation through the direct stimulation of vascular smooth muscle.1,2,3 Thus, acetylcholine or aggregating platelets cause relaxation of arteries with an intact endothelium but cause contraction of arteries denuded of endothelium.1,2,3 An impairment of endothelium-dependent vasodilation has been observed in rabbits4 and monkeys5,6 that were fed an atherogenic diet. Dietary treatment of experimental atherosclerosis in monkeys produced morphologic regression of atherosclerosis and restored endothelium-dependent relaxation to normal.6

Conflicting data exist, however, regarding the existence of endothelium-mediated vasodilation in human coronary arteries. Several in vitro studies conclude that acetylcholine and carbachol, both muscarinic agonists, constrict human coronary arteries,7–10 whereas other studies suggest that acetylcholine dilates normal human coronary arteries.11 Similarly, a discrepancy exists regarding the effect of acetylcholine on human coronary arteries in vivo. After the intracoronary infusion of acetylcholine, Horio et al12 observed at least a 25% decrease in the diameter of normal or almost normal coronary arteries in 27 of 70 arteries, whereas Ludmer et al13 reported an 11% increase in the diameter of normal coronary arteries.

Pathologic studies14 and studies with epicardial echocardiography15 have shown that diffuse atherosclerosis is often present in all three major coronary arteries in patients whose coronary angiograms show atherosclerosis in only one or two coronary arteries. Thus, the coronary arteries that appear angiograph-
ically normal in patients with one- or two-vessel coronary artery disease (CAD) often have inapparent early atherosclerosis and may respond abnormally to an endothelium-dependent vasodilator. Therefore, this study was performed to determine whether or not an endothelium-dependent vasodilator, acetylcholine, causes constriction of angiographically normal coronary arteries in patients with CAD.

**Methods**

**Definitions**

An angiographically normal coronary artery was defined as a vessel with neither a discrete stenosis nor intimal irregularities. An abnormal coronary artery was defined as a vessel with either minimal intimal irregularities or a discrete stenosis. Patients with one or more abnormal vessels were classified as patients with CAD.

**Patients**

The study protocol was approved by the University of Michigan Human Subject Review Committee, Ann Arbor, Michigan, and informed consent was obtained from each patient. Patients with a history of coronary artery spasm or ergonovine-induced coronary artery spasm were excluded.

The study population consisted of 24 patients referred for cardiac catheterization. There were eight patients without CAD. The group consisted of two women and six men ranging in age from 25 to 56 years. The indications for coronary angiography were atypical chest pain in all eight. Four had exercise tolerance tests that were normal, one had an exercise thallium test that showed redistribution suggestive of inferoseptal ischemia, and three did not have exercise tests. There were 16 patients with CAD. The group consisted of 10 men and six women ranging in age from 36 to 77 years. The indications for coronary angiography were chest pain in 14 patients, a recent myocardial infarction in one patient, and ventricular arrhythmias in one patient.

**Protocol**

After completion of the diagnostic cardiac catheterization, a 5F bipolar pacing catheter was positioned in the right ventricular apex and set in the demand mode at approximately 10 beats/min less than the baseline rate. Single-plane coronary cineangiograms were obtained at baseline and after drug injection at 30 frames/sec with standard Judkins catheters. Ionic contrast material was injected at a rate of 5 ml/sec to a total of 8 ml with a Medrad power injector (Cordis, Miami, Florida).

After the baseline coronary angiogram, a 0.2 mM solution of acetylcholine was infused at 0.8–1.6 ml/min for approximately 3 minutes into the coronary ostium through the Judkins catheter. After obtaining the angiogram after acetylcholine injection, a 250 μg bolus of nitroglycerin was injected into the coronary ostium, and a repeat coronary angiogram was obtained.

**Quantitative Coronary Angiography**

Coronary artery diameter was measured with a previously described coronary quantification program that has been validated in studies of intracoronary plastic cylinders in dogs and coronary stenoses in humans. Analysis of intraobserver variability for the measurement of stenosis diameter in the canine coronary artery showed high reproducibility ($r=0.92$, SEE $=0.23$ mm). Similarly, analysis of interobserver variability for stenosis diameter in the human coronary artery showed high reproducibility ($r=0.97$, SEE $=0.19$ mm).

Briefly, the end-diastolic frames of the cineangiograms were projected on a Vanguard viewer that is optically coupled to a video camera. The video signal was digitized onto an ADAC Laboratories (Milpitas, California) digital angiographic computer. The operator chooses a circular region of the digitized angiogram for analysis by positioning a light-pen cursor over the artery and then by adjusting the size of the circular region to encompass the desired segment of the artery to be analyzed. The software uses the catheter as a scaling device to determine absolute diameter.

The arteries were analyzed by a technician who was unaware of the identity of the patient and of the study’s hypothesis and design. The proximal, or occasionally middle, portions of the coronary arteries were analyzed with bends and branch points serving as landmarks to reproducibly measure the same segment after each infusion. Coronary arteries that were inadequately opacified and segments that were overlapped by other structures were not analyzed.

**Statistical Analysis**

A paired $t$ test was used for within-group comparisons of baseline and postinfusion absolute coronary artery diameter, heart rate, and blood pressure. An unpaired $t$ test was used for intergroup comparisons of the drug-induced changes in absolute coronary artery diameter and relative coronary artery diameter (expressed as a percentage of predrug diameter). All data are expressed as mean ± SEM. Differences are considered significant for a $p$ value less than 0.05.

**Results**

**Responses of Coronary Arteries**

Stenotic or irregular segments of six abnormal coronary arteries were analyzed: four left anterior descending arteries, one left circumflex, and one right coronary artery. The mean diameter was $1.80 \pm 0.42$ mm before acetylcholine and $1.26 \pm 0.46$ mm after acetylcholine ($p=0.0025$) (Figure 1) infusion. The mean relative diameter after acetylcholine and nitroglycerin injection, expressed as a fraction of baseline, was 0.62 and 1.12, respectively. Smooth segments of eight abnormal coronary arteries were analyzed. The mean diameter was $3.13 \pm 0.25$ mm before acetylcholine, $2.98 \pm 0.28$ mm after acetylcholine.
line ($p=0.094$), and $3.61 \pm 0.38$ mm after nitroglycerin ($p=0.064$).

Twenty-eight angiographically normal coronary arteries were studied, 14 from the eight patients without CAD, and 14 from 12 patients with one- or two-vessel CAD. The vessels in the group without CAD consisted of eight left anterior descending arteries, five left circumflex arteries, and one right coronary artery. The vessels in the group with CAD were seven left anterior descending arteries and seven left circumflex arteries. The mean baseline coronary artery diameter was $2.93 \pm 0.15$ mm for the patients without CAD and $2.98 \pm 0.25$ mm for the patients with CAD ($p=0.87$). Acetylcholine had a significantly different effect on the diameter of the two groups of angiographically normal coronary arteries (Figure 2). Acetylcholine caused a 0.16-mm increase in coronary artery diameter in the patients without CAD, whereas it caused a 0.26-mm decrease in diameter in the patients with CAD ($p<0.01$). Relative diameter, expressed as fraction of baseline, was 1.06 after acetylcholine and 1.21 after nitroglycerin injection in the patients without CAD. The relative diameter of the angiographically normal coronary arteries in the patients with CAD was 0.91 after acetylcholine ($p=0.006$ vs. no CAD) and 1.09 after nitroglycerin ($p=0.06$ vs. no CAD) injection.

**Hemodynamic Measurements**

Only two right coronary arteries were studied because acetylcholine impairs atrioventricular nodal conduction. Thus, there were no significant changes in the heart rate or mean arterial pressure during the infusion of acetylcholine. Among the patients without CAD, the heart rate was $70 \pm 4$ beats/min before acetylcholine and $68 \pm 4$ beats/min after acetylcholine infusion ($p=0.16$). The mean arterial pressure was $92 \pm 6$ mm Hg before acetylcholine and $89 \pm 5$ after acetylcholine infusion ($p=0.44$). Among the patients with CAD, the heart rate and mean arterial pressure were $70 \pm 3$ beats/min and $93 \pm 3$ mm Hg before acetylcholine, and $72 \pm 2$ beats/min ($p=0.24$) and $96 \pm 3$ mm Hg ($p=0.27$) after acetylcholine infusion. The mean heart rate and arterial pressure of each group were not significantly different before or after acetylcholine infusion.

**Discussion**

The results of this study suggest that acetylcholine, an endothelium-dependent vasodilator, dilates the coronary arteries of patients without evidence of atherosclerotic CAD, whereas angiographically normal coronary arteries in patients with angiographic evidence of CAD constrict in response to acetylcholine. Two recent studies demonstrated that acetylcholine dilates normal human coronary arteries$^{11}$ and internal mammary arteries$^{18}$ in vitro. Regarding previous studies, several possible explanations exist for their conclusions that acetylcholine does not induce endothelium-dependent vasodilation in human coronary arteries.$^{7-10,12}$ One explanation is the erroneous classification of coronary arteries as normal, which is due to the failure of coronary angiography to detect atherosclerosis that is diffuse rather than discrete.$^{14,15}$ The results of previous studies may also be explained by the definitions of “normal” and “vasodilation” that are used.
were applied. Ginsberg et al,7 for example, classified the coronary arteries of four hearts as “normal” despite histologic evidence of atherosclerosis similar in severity to that of transplanted hearts removed because of CAD. The study by Horio et al,12 which reported that intracoronary acetylcholine caused vasoconstriction in 27 of 70 arteries, did not differentiate patients who had stenoses less than 25% from those without detectable coronary artery stenosis. One recent study of intracoronary acetylcholine defined vasoconstriction as an increase in diameter that was 25% or greater of baseline diameter,19 a difference that exceeds the mean increases in diameter observed in the normal patients in the present study after injecting acetylcholine or nitroglycerin.

The EDRF-stimulating effect of acetylcholine is counteracted by a direct contractile action on the smooth muscle.1 Therefore, the observed response to acetylcholine may depend also on the peak concentration of acetylcholine. After infusion into the left coronary artery at 1 ml/min for 2 minutes, a 0.1-mM solution of acetylcholine caused coronary dilatation, whereas a 1.0-mM solution caused constriction in six patients without CAD.20 The present study used a 0.2-mM solution of acetylcholine infused at 0.8–1.6 ml/min, which is similar to that used by Ludmer et al.13 Thus, the vasoconstriction observed by Horio et al12 may be due to their use of bolus injections that may have achieved a high concentration of acetylcholine, a conclusion that is consistent with the pronounced bradycardia induced by bolus injection12,19 but not constant infusions.13

An additional explanation for acetylcholine-induced vasoconstriction in vessels without angiographically detected CAD is unsuspected variant angina. Several studies have demonstrated that intracoronary acetylcholine provokes coronary artery spasm in patients with either normal or abnormal coronary arteries and variant angina.19,21,22 The present study excluded patients with a clinical history that suggested coronary artery spasm or ergonovine-induced coronary artery spasm.

Previously, coronary vasoconstriction due to muscarinic stimulation by methacholine was attributed to a reflex activation of the sympathetic nervous system secondary to system hypotension.23 Although an intracoronary bolus injection of acetylcholine caused bradycardia and hypotension in previous investigations,12,21 the infusion of acetylcholine into the left coronary artery had no significant effect on the patients’ heart rate or blood pressure in this study or in that reported by Ludmer et al.13 The latter study also demonstrated that coronary vaso-constriction during subselective infusion of acetylcholine into the left anterior descending coronary artery was not accompanied by diameter changes of the left circumflex coronary artery, indicating a direct effect of acetylcholine on the arterial wall.13

Expressed as a fraction of the baseline diameter, the mean diameter after acetylcholine was 0.91 for the angiographically normal coronary arteries in patients with CAD, 0.94 for the smooth segments of abnormal arteries, and 0.62 for the stenotic or irregular segments of abnormal coronary arteries. Thus, angiographically abnormal segments demonstrated greater vasoconstriction. Brown et al24 have proposed that vasoactive stimuli cause greater constriction of stenotic compared with nonstenotic segments because the geometric dimensions of certain stenoses may amplify the effect of circumferential smooth muscle shortening on the lumen. According to their hypothesis, 10% outer circumferential shortening of the compliant portion of an eccentric 49% stenosis would increase the percent diameter reduction to 76%, whereas 10% circumferential shortening of the entire circumference of a nonstenotic segment would result in only a 17% diameter reduction.24 Other possible explanations for the greater vasoconstriction of stenotic segments are a more pronounced impairment of EDRF release, an increased sensitivity of the smooth muscle to acetylcholine’s direct vasoconstrictive effect that opposes the endothelium-dependent vasodilation, and the release of endothelium-derived contracting factors.2 Atherosclerotic human coronary arteries have displayed reduced relaxation by substance P, another endothelium-dependent vasodilator, rather than contraction.9,10 Thus, the vasoconstriction induced by acetylcholine may signify that the amount of EDRF released is inadequate to counteract acetylcholine’s direct effect on the muscarinic receptors of the vascular smooth muscle.

Although it is uncertain whether or not the release of EDRF plays an important role in the regulation of coronary artery tone in humans, experimental studies indicate that an impaired ability to release EDRF may facilitate platelet aggregation and coronary vasoconstriction. Aggregating human platelets have relaxed intact canine coronary artery rings primarily because of the release of adenine nucleotides, whereas rings without endothelium have contracted.25 The EDRF released by rabbit aortic endothelium has inhibited the aggregation of human platelets.26 Thus, coronary arteries may be prone to vasospasm at sites of atherosclerotic endothelium because of a diminished inhibition of platelet aggregation and a failure to relax in response to endothelium-dependent vasodilators that are released by platelets.

Although coronary angiography often indicates that atherosclerosis is segmental and may be limited to only one or two vessels, histologic and echocardiographic examination of coronary arteries have shown that CAD is usually diffuse, with few segments that are free of atherosclerosis.14,15 Thus, an abnormal response to vasoactive stimuli may precede the angiographic recognition of CAD. The induction of vasoconstriction by an endothelium-dependent vasodilator such as acetylcholine may provide a useful tool in detecting early endothelial dysfunction and early atherosclerosis. The coronary arteries of cardiac transplant patients, for
example, have constricted in response to acetylcholine despite the absence of angiographic evidence of CAD.27 Although considerable effort is being applied to halt the progression or induce regression of angiographically visible coronary atherosclerosis, it can be postulated that a more effective strategy may be to prevent the development of extensive cell damage and calcification in arteries with early atherosclerosis. The presence of acetylcholine-induced vasoconstriction of angiographically normal coronary arteries, as demonstrated in the present study, provides an important tool to test this hypothesis.

Acknowledgments

We thank Ray Worden and Darrell Debowey for their technical assistance and Vanessa Sims for secretarial assistance.

References


Key Words • acetylcholine • endothelium-derived relaxing factor • vasodilation • vasoconstriction • coronary artery disease
Evidence of endothelial dysfunction in angiographically normal coronary arteries of patients with coronary artery disease.
S W Werns, J A Walton, H H Hsia, E G Nabel, M L Sanz and B Pitt

doi: 10.1161/01.CIR.79.2.287

Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 1989 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/79/2/287